ArticleTranslational lung cancer research2025
First-line immunotherapy in advanced non-squamous non-small cell lung cancer patients with rare mutations: a retrospective cohort study.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Population Pharmacokinetics of Serplulimab and Quantitative Assessment of Transitioning From Weight-Based to Flat-Dosing Strategy.CPT: pharmacometrics & systems pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy has become the standard therapy for advanced non-small cell lung cancer (NSCLC), but its efficacy in patients with rare mutations remains unclear. This study aimed to evaluate the efficacy of first-line immunotherapy in NSCLC patients with rare mutations. Methods: This study selected 2,107 advanced non-squamous NSCLC patients who underwent genetic testing between January 2016 and April 2024 at Peking University Cancer Hospital. Inclusion criteria were patients with rare mutations (including Results: A total of 66 patients with rare mutations and 142 patients with negative mutations were included. Among them, 39 rare mutation patients and 142 mutation-negative patients received first-line immunotherapy, while 27 rare mutation patients received first-line targeted therapy. For patients receiving first-line immunotherapy, there was no significant difference between the rare mutation group and the mutation-negative group in median PFS (14.53 Conclusions: Advanced non-squamous NSCLC patients with rare mutations may benefit from first-line immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.